| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | VACWR025 |
| Uniprot No | P68638 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-263aa |
| 氨基酸序列 | CCTIPSRPINMKFKNSVETDANANYNIGDTIEYLCLPGYRKQKMGPIYAKCTGTGWTLFNQCIKRRCPSPRDIDNGQLDIGGVDFGSSITYSCNSGYHLIGESKSYCELGSTGSMVWNPEAPICESVKCQSPPSISNGRHNGYEDFYTDGSVVTYSCNSGYSLIGNSGVLCSGGEWSDPPTCQIVKCPHPTISNGYLSSGFKRSYSYNDNVDFKCKYGYKLSGSSSSTCSPGNTWKPELPKCVR |
| 预测分子量 | 28.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VACWR025重组蛋白的模拟参考文献示例(基于学术文献常见结构，非真实文献，供参考)：
---
1. **文献名称**：**"Characterization of VACWR025 Recombinant Protein in Vaccinia Virus Replication"**
**作者**：Smith J, et al.
**摘要**：研究通过大肠杆菌表达系统纯化VACWR025重组蛋白，分析其在痘苗病毒(Vaccinia virus)复制周期中的作用。实验表明，VACWR025可能通过与宿主细胞因子相互作用，调控病毒DNA复制效率。
---
2. **文献名称**：**"Structural and Functional Analysis of VACWR025 as a Potential Vaccine Adjuvant"**
**作者**：Li X, Wang Y.
**摘要**：解析了VACWR025重组蛋白的晶体结构，发现其具有免疫刺激性结构域。动物实验显示，该蛋白可增强模型抗原的Th1型免疫应答，提示其在新型疫苗佐剂开发中的应用潜力。
---
3. **文献名称**：**"VACWR025 Recombinant Protein Inhibits Apoptosis in Infected Host Cells"**
**作者**：Garcia R, et al.
**摘要**：研究表明，VACWR025重组蛋白通过抑制宿主细胞线粒体凋亡通路，延缓病毒感染早期细胞死亡，为痘苗病毒逃逸宿主防御的机制提供了新见解。
---
4. **文献名称**：**"High-Yield Production of VACWR025 in Insect Cell Expression Systems"**
**作者**：Chen T, et al.
**摘要**：优化了杆状病毒-昆虫细胞系统中VACWR025重组蛋白的表达条件，实现了高产量可溶性蛋白制备，并验证其抗原性可用于抗体开发及诊断工具研究。
---
**注意**：以上文献为示例性质，实际研究中请通过PubMed、Google Scholar等平台搜索真实文献(关键词如“VACWR025 recombinant protein”或“Vaccinia virus WR025”)。
**Background of VACWR025 Recombinant Protein**
VACWR025 is a protein encoded by the vaccinia virus (VACV) Western Reserve (WR) strain, a member of the *Poxviridae* family. As a large, double-stranded DNA virus, vaccinia has been extensively studied as a model for understanding poxvirus biology and host-pathogen interactions. The WR strain, in particular, is widely used in research due to its relevance in vaccine development (e.g., smallpox vaccine) and oncolytic virotherapy.
The VACWR025 gene, also annotated as C11R in some VACV strains, is located in the viral genome's conserved core region. While its precise functional role remains under investigation, bioinformatic analyses suggest it may contribute to viral replication, immune evasion, or modulation of host cell processes. Proteins encoded by poxviruses often exhibit multifunctional properties, including interference with host antiviral signaling pathways (e.g., NF-κB or interferon responses), which are critical for viral survival and pathogenesis. Recombinant VACWR025 protein is generated via heterologous expression systems (e.g., *E. coli* or mammalian cells) to enable biochemical and immunological studies.
Research on VACWR025 aims to elucidate its structure, interaction partners, and role in viral replication cycles. Such insights could inform antiviral strategies or improve vaccine design by targeting conserved viral components. Additionally, recombinant VACWR025 may serve as a tool for screening antiviral compounds or developing diagnostic assays. Its study also contributes to understanding the evolutionary adaptation of poxviruses to host immune defenses.
In summary, VACWR025 represents a functionally intriguing vaccinia protein with potential applications in virology, immunology, and therapeutic development, underscoring the importance of characterizing viral proteins in combatting poxviral infections.
×
